Nuo Therapeutics — Third Quarter 2026 Earnings Summary
Nuo Therapeutics reported total revenues of approximately $1.9 million for the third quarter of 2026, representing an 80% increase compared to the same period in 2025. The company recorded a net operating loss of roughly $374,000 for the quarter, which was an improvement over the prior year but higher than the previous quarter due to increased stock-based compensation and regulatory costs. Financial updates indicate the receipt of a $250,000 reimbursement milestone from Smith+Nephew and the final funding of a loan agreement, bringing total borrowings to $2 million. Additionally, the company highlighted favorable 2027 Medicare reimbursement rulings for its Aurix product, including a 7% increase in Outpatient Prospective Payment System rates and expanded coverage for nursing home treatments effective January 1, 2027.
- Company
- NUO THERAPEUTICS INC
- Sector
- Healthcare
- Industry
- Medical Devices